Efficacy of Thymosin Alpha 1 in the Treatment of COVID-19: A Multicenter Cohort Study

• DOI: 10.3389/fimmu.2021.673693
• Publication Date: 2021-08-02T09:09:48Z
• Authors: Jiao Liu; Yanfei Shen; Zhenliang Wen; Qianghong Xu; Zhixiong Wu; Huibin Feng; Zhongyi Li; Xuan Dong; Sisi Huang; Jun Guo; Lidi Zhang; Yizhu Chen; Wenzhe Li; Wei Zhu; Hangxiang Du; Yongan Liu; Tao Wang; Limin Chen; Jean-Louis Teboul; Djillali Annane; Dechang Chen
• Keywords: SOFA score; Clinical endpoint

Background Thymosin alpha 1 (Tα1) is widely used to treat patients with COVID-19 in China; however, its efficacy remains unclear. This study aimed explore the of Tα1 as a therapy. Methods We performed multicenter cohort five tertiary hospitals Hubei province China between December 2019 and March 2020. The patient non-recovery rate was primary outcome. Results All crude outcomes, including (65/306 vs. 290/1,976, p = 0.003), in-hospital mortality (62/306 271/1,976, intubation (31/306 106/1,976, 0.001), acute respiratory distress syndrome (ARDS) incidence (104/306 499/1,976, kidney injury (AKI) (26/306 66/1,976, < length intensive care unit (ICU) stay (14.9 ± 12.7 8.7 8.2 days, were significantly higher treatment group. After adjusting for confounding factors, use found be associated than non-Tα1 (OR 1.5, 95% CI 1.1–2.1, 0.028). An increased risk observed subgroups maximum sequential organ failure assessment (SOFA) scores ≥2 2.0, 95%CI 1.4–2.9, 0.024), record ICU admission 5.4, 2.1–14.0, lower PaO2/FiO2 values 1.9, 1.1–3.4, 0.046). Furthermore, later initiation rate. Conclusion an rate, especially those greater disease severity.